Ipilimumab
Antitumor Activity of Ipilimumab or BRAF ± MEK Inhibition After Pembrolizumab Treatment in Patients With Advanced Melanoma: Analysis From KEYNOTE-006
Nivolumab Plus Low-Dose Ipilimumab in Previously Treated Patients With Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: 4-Year Follow-Up From CheckMate 142☆
Baseline Gut Microbiota Predicts Clinical Response and Colitis in Metastatic Melanoma Patients Treated With Ipilimumab